Uniphar (DUB:UPR) Long-Term Debt: €355 Mil (As of Dec. 2025)


DUB:UPR Uniphar PLC DUB:UPR
81 GF Score
Price €4.80
GF Value €3.64
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Uniphar Long-Term Debt?

Uniphar DUB:UPR +0.42% 81 Long-Term Debt is €355 Mil as of Dec. 2025. GuruFocus rates DUB:UPR with a GF Score™ of 81/100 and a GF Value™ of €3.64 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Uniphar's Long-Term Debt for the quarter that ended in Dec. 2025 was €355 Mil.

Uniphar's quarterly Long-Term Debt increased from Dec. 2024 (€242 Mil) to Jun. 2025 (€312 Mil) and increased from Jun. 2025 (€312 Mil) to Dec. 2025 (€355 Mil).

Uniphar's annual Long-Term Debt increased from Dec. 2023 (€223 Mil) to Dec. 2024 (€242 Mil) and increased from Dec. 2024 (€242 Mil) to Dec. 2025 (€355 Mil).

Uniphar  (DUB:UPR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Uniphar Long-Term Debt Related Terms

Uniphar Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Uniphar's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Uniphar Long-Term Debt Chart

Uniphar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.60 187.43 222.60 241.65 355.07

Uniphar Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 222.60 239.18 241.65 311.60 355.07
DUB:UPR
81GF Score
Uniphar PLC DUB:UPR
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €355 Mil mean?
Uniphar (DUB:UPR) has a Long-Term Debt of €355 Mil as of Dec. 2025.
Is Uniphar's Long-Term Debt too high?
Uniphar's current Long-Term Debt is €355 Mil. Overall, Uniphar has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Long-Term Debt compare to MCK and CAH?
Uniphar's Long-Term Debt of €355 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Distribution company?
A good Long-Term Debt depends on the Medical Distribution industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Uniphar's current Long-Term Debt is €355 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.80 — trading 31.9% above its estimated fair value. The current Long-Term Debt is €355 Mil. Uniphar's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current Long-Term Debt is €355 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Uniphar (DUB:UPR) Overvalued in 2026?

Based on GuruFocus' analysis, Uniphar stock appears to be overvalued. The current stock price of €4.80 is trading 31.9% above its estimated GF Value™ of €3.64. GuruFocus considers Uniphar to be Significantly Overvalued.

Key valuation signals for DUB:UPR:

  • Long-Term Debt: €355 Mil
  • GF Value™: €3.64 vs. price of €4.80 (31.9% above fair value)
  • GF Score™: 81/100 with 9 warning signs

No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Uniphar Business Description

Other Exchanges UPR:UK0NR:Germany
Address 4045 Kingswood Road, Citywest Business Park, Dublin, IRL, D24 V06K
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
81GF Score

Get the complete analysis for DUB:UPR

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.80
Price
€3.64
GF Value